ILMN vs NTRA
ILMN: Illumina provides the essential genetic sequencing and array platforms that power modern genomic research and clinical diagnostics. NTRA: Natera is a pioneer in cell-free DNA testing, providing advanced genetic insights across prenatal, oncology, and organ health applications.
Side-by-side fundamentals
| Metric | ILMN | NTRA | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $267.93 | $405.92 | |
| Market cap | $40.5B | $58.5B | |
| P/E as of 2026-10-20 | 49.99 | n/a | |
| Net margin FY2025, SEC XBRL | +19.6% | -9.0% | ILMN higher |
| Gross margin FY2025, SEC XBRL | +66.1% | n/a | |
| Operating margin FY2025, SEC XBRL | +18.6% | -13.4% | ILMN higher |
| ROE FY2025, SEC XBRL | +31.2% | -12.2% | ILMN higher |
| ROA FY2025, SEC XBRL | +12.8% | -8.7% | ILMN higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | n/a | 0.04 | |
| Revenue growth (YoY) FY2025, SEC XBRL | -0.7% | +35.9% | NTRA higher |
| Revenue CAGR (3y) SEC XBRL | -1.4% | +41.1% | NTRA higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-02 | 1.01 | 1.29 | |
| 1-year return as of 2026-10-20 close | +169.3% | +115.2% | ILMN higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.